S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
NASDAQ:FOLD

Amicus Therapeutics (FOLD) Stock Price, News & Analysis

$10.66
-0.02 (-0.19%)
(As of 04/15/2024 ET)
Today's Range
$10.59
$10.81
50-Day Range
$10.66
$14.00
52-Week Range
$9.70
$14.57
Volume
2.75 million shs
Average Volume
2.30 million shs
Market Capitalization
$3.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00

Amicus Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
87.6% Upside
$20.00 Price Target
Short Interest
Bearish
11.00% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.28
Upright™ Environmental Score
News Sentiment
1.14mentions of Amicus Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.75 M Sold Last Quarter
Proj. Earnings Growth
1,600.00%
From $0.02 to $0.34 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.76 out of 5 stars

Medical Sector

228th out of 928 stocks

Pharmaceutical Preparations Industry

92nd out of 432 stocks

FOLD stock logo

About Amicus Therapeutics Stock (NASDAQ:FOLD)

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

FOLD Stock Price History

FOLD Stock News Headlines

Amicus Therapeutics Becomes Oversold (FOLD)
Nerd Investor Reveals Secret To Make Money With A.I.
He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.
FOLD Jul 2024 12.000 call
FOLD Oct 2024 12.000 call
Nerd Investor Reveals Secret To Make Money With A.I.
He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.
FOLD Jan 2025 12.000 put
FOLD Jul 2024 9.000 put
Q4 2023 Amicus Therapeutics Inc Earnings Call
Buy Rating Affirmed for Amicus with Strong Growth and Promising Outlook
See More Headlines
Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/15/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:FOLD
CUSIP
03152W10
Employees
517
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$20.00
High Stock Price Target
$22.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+87.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-151,580,000.00
Pretax Margin
-37.59%

Debt

Sales & Book Value

Annual Sales
$399.36 million
Book Value
$0.55 per share

Miscellaneous

Free Float
289,180,000
Market Cap
$3.15 billion
Optionable
Optionable
Beta
0.75

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

FOLD Stock Analysis - Frequently Asked Questions

Should I buy or sell Amicus Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FOLD shares.
View FOLD analyst ratings
or view top-rated stocks.

What is Amicus Therapeutics' stock price target for 2024?

3 brokers have issued 1-year target prices for Amicus Therapeutics' shares. Their FOLD share price targets range from $19.00 to $22.00. On average, they anticipate the company's share price to reach $20.00 in the next year. This suggests a possible upside of 87.6% from the stock's current price.
View analysts price targets for FOLD
or view top-rated stocks among Wall Street analysts.

How have FOLD shares performed in 2024?

Amicus Therapeutics' stock was trading at $14.19 at the beginning of 2024. Since then, FOLD stock has decreased by 24.9% and is now trading at $10.66.
View the best growth stocks for 2024 here
.

When is Amicus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our FOLD earnings forecast
.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) issued its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.05. The biopharmaceutical company earned $115.08 million during the quarter, compared to analysts' expectations of $115.11 million. Amicus Therapeutics had a negative trailing twelve-month return on equity of 119.46% and a negative net margin of 37.96%.

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.04%) and Fulton Bank N.A. (0.00%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Ellen Rosenberg, Jeff Castelli, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends
.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FOLD) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners